Literature DB >> 783194

Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones.

A Burger, D Dinichert, P Nicod, M Jenny, T Lemarchand-Béraud, M B Vallotton.   

Abstract

2-n-Butyl-3-(4'-diethylaminoethoxy-3',5'-diiodobenzoyl)-benzofurane (amiodarone), a drug used in arrythmias and angina pectoris, contains 75 mg of organic iodine/200 mg active substance. Four studies were performed to test its effect on thyroid hormone metabolism: (a) nine male subjects were treated with 400 mg of amiodarone for 28 days; (b) five male subjects received, for the same period of time, 150 mg of iodine in the form of Lugol's solution; (c) five subjects received 300 mug L-thyroxine (T4) for 16 days; from the 10th to the 16th day, 400 mg of amiodarone was added; and (d) five euthyroid subjects received 300 mug L-T4 for 16 days. The changes in serum thyroid-stimulating hormone (TSH), serum total T4, 3,5,3'-triiodothyronine (T3), free T3, and 3,5',3'-triiodothyronine (reverse T3, rT3) were measured, and the pituitary reserve in TSH was evaluated by a thyrotropin-releasing hormone (TRH) test. The results show that amiodarone induced a decrease in serum T3 (28+/-5.1 ng/100 ml, mean+/-SEM, P less than 0.0S and 82.7+/-9.3 ng rT3/100 ml, P less than 0.01). The control study with an equal amount of inorganic iodine did not induce these opposite changes but slightly lowered serum rT3, T3, and T4. In the third study, serum rT3 increased as under amiodarone treatment, thereby proving that these changes were peripheral. It is suggested that amiodarone changes thyroid hormone metabolism, possibly by reducing deiodination of T4 to T3 and inducing a preferential production of rT3. Amiodarone also increased the response of TSH to TRH. The maximal increment of serum TSH above base line was 32+/-4.5 muU/ml under treatment and 20+/-3 muU/ml before treatment (P less than 0.01). During this test, the serum T3 increase was more pronounced than during the control period (83+/-13 and 47+/-7.4 ng/100 ml, P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 783194      PMCID: PMC333177          DOI: 10.1172/JCI108466

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  The effect of butyl-4-hydroxy-3:5-diiodobenzoate on the availability of thyroid hormones to peripheral tissues in isotopically equilibrated rats.

Authors:  F ESCOBAR DEL REY; G MORREALE DE ESCOBAR
Journal:  Acta Endocrinol (Copenh)       Date:  1962-05

Review 2.  Extrathyroid effects of some antithyroid drugs and their metabolic consequences.

Authors:  G Morreale de Escobar; F Escobar del Rey
Journal:  Recent Prog Horm Res       Date:  1967

3.  Control of thyroid hormone secretion in normal subjects receiving iodides.

Authors:  A G Vagenakis; P Downs; L E Braverman; A Burger; S H Ingbar
Journal:  J Clin Invest       Date:  1973-02       Impact factor: 14.808

4.  Diversion of peripheral thyroxine metabolism from activating to inactivating pathways during complete fasting.

Authors:  A G Vagenakis; A Burger; G I Portnary; M Rudolph; J R O'Brian; F Azizi; R A Arky; P Nicod; S H Ingbar; L E Braverman
Journal:  J Clin Endocrinol Metab       Date:  1975-07       Impact factor: 5.958

5.  Rapid simultaneous radioimmunoassay for triiodothyronine and thyroxine in unextracted serum.

Authors:  T Mitsuma; J Colucci; L Shenkman; C S Hollander
Journal:  Biochem Biophys Res Commun       Date:  1972-03-24       Impact factor: 3.575

6.  Determination of thyroxine-binding globulin. A simplified procedure utilizing dextran-coated charcoal.

Authors:  R C Roberts; T F Nikolai
Journal:  Clin Chem       Date:  1969-12       Impact factor: 8.327

7.  Radioimmunoassays of 3,5,3'-triiodo-L-thyronine with and without a prior extraction step.

Authors:  A Burger; C Sakoloff; V Staeheli; M B Vallotton; S H Ingbar
Journal:  Acta Endocrinol (Copenh)       Date:  1975-09

8.  Reciprocal changes in serum concentrations of 3,3',5-triiodothyronine (T3) in systemic illnesses.

Authors:  I J Chopra; U Chopra; S R Smith; M Reza; D H Solomon
Journal:  J Clin Endocrinol Metab       Date:  1975-12       Impact factor: 5.958

9.  Inhibition of L-thyroxine monodeiodination by thyroxine analogs.

Authors:  F C LARSON; E C ALBRIGHT
Journal:  J Clin Invest       Date:  1961-07       Impact factor: 14.808

10.  A radioimmunoassay for measurement of 3,3',5'-triiodothyronine (reverse T3).

Authors:  I J Chopra
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

View more
  62 in total

1.  Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment.

Authors:  Matthew L Rosene; Gábor Wittmann; Rafael Arrojo e Drigo; Praful S Singru; Ronald M Lechan; Antonio C Bianco
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

2.  Observations on the factors that control the generation of triiodothyronine from thyroxine in rat liver and the nature of the defect induced by fasting.

Authors:  A Balsam; S H Ingbar
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

3.  Antagonism of thyroid hormone action by amiodarone in rat pituitary tumor cells.

Authors:  M F Norman; T N Lavin
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

Review 4.  [Thyroid and treatment with amiodarone diagnosis, therapy and clinical management].

Authors:  Peter Mikosch
Journal:  Wien Med Wochenschr       Date:  2008

5.  Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism.

Authors:  Andrea Hofmann; Clemens Nawara; Sedat Ofluoglu; Johannes Holzmannhofer; Bernhard Strohmer; Christian Pirich
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

6.  Amiodarone-induced thyrotoxicosis: four cases and a review of the literature.

Authors:  S Keidar; E Grenadier; A Palant
Journal:  Postgrad Med J       Date:  1980-05       Impact factor: 2.401

7.  Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3'-triiodothyroacetic acid (TRIAC).

Authors:  P Beck-Peccoz; G Piscitelli; M G Cattaneo; G Faglia
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

Review 8.  [Total thyroidectomy in patients with amiodarone-induced hyperthyroidism: when does the risk of conservative treatment exceed the risk of surgery?].

Authors:  C Meerwein; D Vital; M Greutmann; C Schmid; G F Huber
Journal:  HNO       Date:  2014-02       Impact factor: 1.284

Review 9.  The clinician and the thyroid.

Authors:  H J Biersack; A Hotze
Journal:  Eur J Nucl Med       Date:  1991

10.  Amiodarone-induced thyrotoxicosis: is there a place for surgery?

Authors:  M Meurisse; E Hamoir; M D'Silva; J Joris; G Hennen
Journal:  World J Surg       Date:  1993 Sep-Oct       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.